Royce & Associates LP Buys New Position in Teleflex Incorporated $TFX

Royce & Associates LP purchased a new position in shares of Teleflex Incorporated (NYSE:TFX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 70,000 shares of the medical technology company’s stock, valued at approximately $8,565,000. Royce & Associates LP owned approximately 0.16% of Teleflex at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Empowered Funds LLC grew its stake in shares of Teleflex by 15.8% in the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock worth $233,000 after acquiring an additional 230 shares in the last quarter. Jane Street Group LLC boosted its holdings in Teleflex by 42.6% during the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock worth $877,000 after purchasing an additional 1,895 shares during the last quarter. Teacher Retirement System of Texas grew its position in Teleflex by 31.5% in the 2nd quarter. Teacher Retirement System of Texas now owns 11,819 shares of the medical technology company’s stock worth $1,399,000 after purchasing an additional 2,831 shares in the last quarter. Arkadios Wealth Advisors increased its stake in Teleflex by 61.8% in the 2nd quarter. Arkadios Wealth Advisors now owns 5,403 shares of the medical technology company’s stock valued at $639,000 after buying an additional 2,064 shares during the last quarter. Finally, Strs Ohio increased its stake in Teleflex by 4.9% in the 2nd quarter. Strs Ohio now owns 23,067 shares of the medical technology company’s stock valued at $2,730,000 after buying an additional 1,067 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

Teleflex Price Performance

Shares of NYSE TFX opened at $122.02 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The stock has a fifty day simple moving average of $111.31 and a two-hundred day simple moving average of $118.70. Teleflex Incorporated has a 1-year low of $100.18 and a 1-year high of $143.32. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of -5.94, a price-to-earnings-growth ratio of 0.76 and a beta of 0.87.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The business’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, March 6th. Teleflex’s dividend payout ratio is presently -6.62%.

Wall Street Analyst Weigh In

TFX has been the topic of a number of research analyst reports. Zacks Research downgraded Teleflex from a “hold” rating to a “strong sell” rating in a research note on Monday. Needham & Company LLC lifted their price target on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Wall Street Zen downgraded Teleflex from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Wells Fargo & Company lifted their target price on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $140.83.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.